AIM: To investigate the behaviour of total plasma homocysteine (tHcy) and its most common genetic determinant defect, the methylenetetrahydrofolate reductase C677T (C677TMTHFR) polymorphism in patients with early stage colorectal carcinoma. METHODS: tHcy was quantified by Abbott IMx immunoassay; screening for C677TMTHFR substitution was performed by PCR and restriction analysis. RESULTS: The frequency of the C/T and T/T genotypes of the C677TMTHFR gene polymorphism did not differ between the groups. The mean tHcy was statistically higher in cancer patients than in control subjects carrying the same C/C or C/T genotype, whereas there was no difference in the T/T homozygous carriers of the two groups. tHcy was significantly higher in the T/T homozygous carriers than in C/C and C/T genotype carriers. CONCLUSION: The statistically significant increase of tHcy observed in C/C and C/T genotype carriers among our cancer patients is related to substrate consumption dependent on the tumor cell proliferation rate, whereas the tHcy increase observed in T/T genotype carriers of both groups probably depends on the enzymatic deficit of the homocysteine conversion to methionine and/or on the folate deficiency.
AIM: To investigate the behaviour of total plasma homocysteine (tHcy) and its most common genetic determinant defect, the methylenetetrahydrofolate reductase C677T (C677TMTHFR) polymorphism in patients with early stage colorectal carcinoma. METHODS:tHcy was quantified by Abbott IMx immunoassay; screening for C677TMTHFR substitution was performed by PCR and restriction analysis. RESULTS: The frequency of the C/T and T/T genotypes of the C677TMTHFR gene polymorphism did not differ between the groups. The mean tHcy was statistically higher in cancerpatients than in control subjects carrying the same C/C or C/T genotype, whereas there was no difference in the T/T homozygous carriers of the two groups. tHcy was significantly higher in the T/T homozygous carriers than in C/C and C/T genotype carriers. CONCLUSION: The statistically significant increase of tHcy observed in C/C and C/T genotype carriers among our cancerpatients is related to substrate consumption dependent on the tumor cell proliferation rate, whereas the tHcy increase observed in T/T genotype carriers of both groups probably depends on the enzymatic deficit of the homocysteine conversion to methionine and/or on the folate deficiency.
Authors: R Abbate; I Sardi; G Pepe; R Marcucci; T Brunelli; D Prisco; C Fatini; M Capanni; I Simonetti; G F Gensini Journal: Thromb Haemost Date: 1998-04 Impact factor: 5.249
Authors: B Christensen; P Frosst; S Lussier-Cacan; J Selhub; P Goyette; D S Rosenblatt; J Genest; R Rozen Journal: Arterioscler Thromb Vasc Biol Date: 1997-03 Impact factor: 8.311
Authors: M E Martínez; T Maltzman; J R Marshall; J Einspahr; M E Reid; R Sampliner; D J Ahnen; S R Hamilton; D S Alberts Journal: Cancer Res Date: 1999-10-15 Impact factor: 12.701
Authors: P Simioni; P Prandoni; A Burlina; D Tormene; C Sardella; V Ferrari; L Benedetti; A Girolami Journal: Thromb Haemost Date: 1996-12 Impact factor: 5.249
Authors: P Frosst; H J Blom; R Milos; P Goyette; C A Sheppard; R G Matthews; G J Boers; M den Heijer; L A Kluijtmans; L P van den Heuvel Journal: Nat Genet Date: 1995-05 Impact factor: 38.330
Authors: M den Heijer; T Koster; H J Blom; G M Bos; E Briet; P H Reitsma; J P Vandenbroucke; F R Rosendaal Journal: N Engl J Med Date: 1996-03-21 Impact factor: 91.245
Authors: Viktor Komlósi; Erika Hitre; Eva Pap; Vilmos Adleff; Andrea Réti; Eva Székely; Anna Bíró; Péter Rudnai; Bernadette Schoket; Judit Müller; Béla Tóth; Szabolcs Ottó; Miklós Kásler; Judit Kralovánszky; Barna Budai Journal: BMC Cancer Date: 2010-10-04 Impact factor: 4.430